Financhill
Back

Evolus Quote, Financials, Valuation and Earnings

Evolus Price Quote

$10.90
+0.01 (+0.28%)
(Updated: December 21, 2024 at 5:24 AM ET)

Evolus Key Stats

Sell
22
Evolus (EOLS) is a Sell

Day range:
$10.73 - $11.16
52-week range:
$9.80 - $17.82
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.65
P/B ratio:
117.07%

Volume:
975.4K
Avg. volume:
627.6K
1-year change:
12.5%
Market cap:
$689.6M
Revenue:
$202.1M
EPS:
$-0.9

How Much Does Evolus Make?

Data Unavailable

Is Evolus Growing As A Company?

Data Unavailable

Evolus Stock Price Performance

  • Did Evolus Stock Go Up Last Month?
    Evolus share price went down by -13.78% last month
  • Did EOLS's Share Price Rise Over The Last Year?
    EOLS share price rose by 12.5% over the past 1 year

What Is Evolus 52-Week High & Low?

  • What Is Evolus’s 52-Week High Share Price?
    Evolus has traded as high as $17.82 over the past 52 weeks
  • What Is Evolus’s 52-Week Low Share Price?
    Evolus has traded as low as $9.80 over the past 52 weeks

Evolus Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Evolus?

Data Unavailable

Is Evolus Cash Flow Positive?

Data Unavailable

Evolus Return On Invested Capital

Data Unavailable

Evolus Earnings Date & Stock Price

  • What Is Evolus's Stock Price Today?
    A single share of EOLS can be purchased today for 10.89
  • What Is Evolus’s Stock Symbol?
    Evolus trades on the nasdaq under the ticker symbol: EOLS
  • When Is Evolus’s Next Earnings Date?
    The next quarterly earnings date for Evolus is scheduled on March 7, 2025
  • When Is EOLS's next ex-dividend date?
    Evolus's next ex-dividend date is December 22, 2024
  • How To Buy Evolus Stock?
    You can buy Evolus shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Evolus Competitors

  • Who Are Evolus's Competitors?
    Below is a list of companies who compete with Evolus or are related in some way:
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Myomo Inc (MYO)
    • Insulet Corp (PODD)
    • Xtant Medical Holdings Inc (XTNT)

Evolus Dividend Yield

Data Unavailable

Evolus Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -66.67%
Revenue: 22.12% -3.66%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable